Charles River Laboratories International (CRL) Receivables (2009 - 2025)

Charles River Laboratories International (CRL) has reported Receivables for 17 consecutive years, with $719.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables changed 0.22% year-over-year to $719.3 million; the TTM figure through Dec 2025 stood at $719.3 million (changed 0.22% YoY), while the FY2025 annual figure was $719.3 million, changed 0.22% from the prior year.
• Receivables came in at $719.3 million for Q4 2025 at Charles River Laboratories International, down from $748.3 million in the prior quarter.
• The five-year high for Receivables was $818.7 million in Q3 2023, with the low at $610.6 million in Q1 2021.
• Average Receivables over 5 years is $742.4 million, with a median of $755.4 million recorded in 2024.
• Across the five-year window, Receivables increased 22.35% in 2021 and slipped 10.57% in 2024, its largest moves.
• Year by year, Receivables stood at $657.6 million in 2021, then advanced by 14.42% to $752.4 million in 2022, then gained by 7.14% to $806.1 million in 2023, then retreated by 10.57% to $720.9 million in 2024, then declined by 0.22% to $719.3 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $719.3 million, $748.3 million, and $780.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.